Searchable abstracts of presentations at key conferences in endocrinology
Endocrine Abstracts (2017) 49 EP619 | DOI: 10.1530/endoabs.49.EP619

1Endocrinology and Nutrition Unit, Hospital Miguel Servet, Zaragoza, Spain; 2Laboratory of Clinical Biochemistry, Hospital Miguel Servet, Zaragoza, Spain.


Objective: To study the relation between incretin-based therapies, DPP-4 inhibitors and GLP-1 receptor agonists, and tumor stage at the time of diagnosis of pancreatic and biliary tract cancer.

Methods: Retrospective study of type 2 diabetic patients with newly diagnosed of pancreatic or biliary tract cancer attended consecutively in a tertiary hospital between the years 2012 and 2015.

Results: A total of 37 patients were included. The prevalence of use for DPP-4 inhibitors in our cohort was 37.8% (sitagliptin, linagliptin and vildagliptin). No one patient was under treatment with GLP-1 receptor agonists. Subjects’ characteristics are shown in Table 1. Men developed cancer earlier than women (68.4 vs 75.5 years, P=0.038). Smoking prevalence and time of diabetes evolution was higher for males. Subjects who were taking DPP4-i exhibited stages more advanced at diagnosis (Table 2). However, this result did not reach statistically significant differences (70 vs 50%, P=0.250). Metformin use was not associated with different tumor staging (P=0.169).

Conclusions: This study supports DPP4-i safety from the point of view of tumorigenesis in humans. However, the small sample size due to the low incidence of this lethal disease makes us to be cautious in the conclusions. Further research is needed in order to ensure that incretin-based therapies are safe from the oncological point of view.

/images/missingimage.jpg /images/missingimage.jpg

Volume 49

19th European Congress of Endocrinology

Lisbon, Portugal
20 May 2017 - 23 May 2017

European Society of Endocrinology 

Browse other volumes

Article tools

My recent searches

No recent searches.

My recently viewed abstracts